These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

580 related articles for article (PubMed ID: 14983406)

  • 1. Serum IL-18 levels are not increased in patients with untreated Graves' ophthalmopathy.
    Wakelkamp IM; Prummel MF; Wiersinga WM
    Horm Metab Res; 2004 Jan; 36(1):44-7. PubMed ID: 14983406
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The balance shift in Th1/Th2 related IL-12/IL-5 cytokines in Graves' disease during methimazole therapy.
    Molnár I
    Autoimmunity; 2007 Feb; 40(1):31-7. PubMed ID: 17364495
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum Th1 and Th2 profile cytokine level changes in patients with Graves' ophthalmopathy treated with corticosteroids.
    Myśliwiec J; Kretowski A; Topolska J; Siewko K; Jakubczyk D; Szelachowska M; Mikita A; Kinalska I
    Horm Metab Res; 2001 Dec; 33(12):739-43. PubMed ID: 11753760
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peripheral parameters of oxidative stress in patients with infiltrative Graves' ophthalmopathy treated with corticosteroids.
    Bednarek J; Wysocki H; Sowiński J
    Immunol Lett; 2004 May; 93(2-3):227-32. PubMed ID: 15158621
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum cytokines levels in Graves' disease.
    Al-Humaidi MA
    Saudi Med J; 2000 Jul; 21(7):639-44. PubMed ID: 11500727
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detectable serum IgE levels in Graves' ophthalmopathy.
    Molnár I; Horváth S; Balázs C
    Eur J Med Res; 1996 Sep; 1(11):543-6. PubMed ID: 9438158
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increase of interferon-gamma-inducible CXC chemokine CXCL10 serum levels in patients with active Graves' disease, and modulation by methimazole therapy.
    Antonelli A; Rotondi M; Fallahi P; Romagnani P; Ferrari SM; Barani L; Ferrannini E; Serio M
    Clin Endocrinol (Oxf); 2006 Feb; 64(2):189-95. PubMed ID: 16430719
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum levels of the interferon-gamma-inducible alpha chemokine CXCL10 in patients with active Graves' disease, and modulation by methimazole therapy and thyroidectomy.
    Antonelli A; Fallahi P; Rotondi M; Ferrari SM; Serio M; Miccoli P
    Br J Surg; 2006 Oct; 93(10):1226-31. PubMed ID: 16838393
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum antibodies to collagen XIII: a further good marker of active Graves' ophthalmopathy.
    De Bellis A; Sansone D; Coronella C; Conte M; Iorio S; Perrino S; Battaglia M; Bellastella G; Wall JR; Bellastella A; Bizzarro A
    Clin Endocrinol (Oxf); 2005 Jan; 62(1):24-9. PubMed ID: 15638866
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of abnormal thyroid function on the severity of Graves' ophthalmopathy.
    Prummel MF; Wiersinga WM; Mourits MP; Koornneef L; Berghout A; van der Gaag R
    Arch Intern Med; 1990 May; 150(5):1098-101. PubMed ID: 1691908
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Th1/Th2 cytokines in patients with Graves' disease with or without ophthalmopathy.
    Esfahanian F; Naimi E; Doroodgar F; Jadali Z
    Iran J Allergy Asthma Immunol; 2013 May; 12(2):168-75. PubMed ID: 23754356
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thyrotropin receptor antibodies detected by the human recombinant TBII assay--a surrogate marker for autoimmune activity in Graves' ophthalmopathy?
    Myśliwiec J; Kretowski A; Stepień A; Mirończuk K; Kinalska I
    Med Sci Monit; 2002 Sep; 8(9):MT159-62. PubMed ID: 12218953
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical results of anti-inflammatory therapy in Graves' ophthalmopathy and association with thyroidal autoantibodies.
    Eckstein AK; Plicht M; Lax H; Hirche H; Quadbeck B; Mann K; Steuhl KP; Esser J; Morgenthaler NG
    Clin Endocrinol (Oxf); 2004 Nov; 61(5):612-8. PubMed ID: 15521965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decreased nerve growth factor levels in hyperthyroid Graves' ophthalmopathy highlighting the role of neuroprotective factor in autoimmune thyroid diseases.
    Molnár I; Bokk A
    Cytokine; 2006 Aug; 35(3-4):109-14. PubMed ID: 17008110
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Soluble intercellular adhesion molecule-1 (sICAM-1) in Graves' disease.
    Balázs C; Kiss E
    Acta Microbiol Immunol Hung; 1994; 41(4):451-6. PubMed ID: 7866729
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma leptin concentrations in patients with Graves' disease with or without ophthalmopathy.
    Ozata M; Uckaya G; Bolu E; Corapcioglu D; Bingol N; Ozdemir IC
    Med Sci Monit; 2001; 7(4):696-700. PubMed ID: 11433197
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative study on IgG and IgA antibodies against human thyroid and eye-muscle antigens in Graves' ophthalmopathy.
    Molnár I; Balázs C
    Acta Med Hung; 1991; 48(1-2):13-21. PubMed ID: 1813853
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum concentrations of proinflammatory cytokines in Graves' disease: effect of treatment, thyroid function, ophthalmopathy and cigarette smoking.
    Salvi M; Pedrazzoni M; Girasole G; Giuliani N; Minelli R; Wall JR; Roti E
    Eur J Endocrinol; 2000 Aug; 143(2):197-202. PubMed ID: 10913938
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum interferon gamma levels in autoimmune thyroid disease.
    Matsubayashi S; Kasuga Y; Sakatsume Y; Akasu F; Volpé R
    Clin Invest Med; 1990 Oct; 13(5):271-4. PubMed ID: 2125901
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Binding, stimulating and blocking TSH receptor antibodies to the thyrotropin receptor as predictors of relapse of Graves' disease after withdrawal of antithyroid treatment.
    Quadbeck B; Hoermann R; Hahn S; Roggenbuck U; Mann K; Janssen OE
    Horm Metab Res; 2005 Dec; 37(12):745-50. PubMed ID: 16372228
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.